PGR and Gynecomastia: Phase 3 trials demonstrated negligible endocrine side effects (e.g., ≤1% gynecomastia vs. 10%-15% with Spironolactone), validating its minimal off-target interactions with androgen or progesterone receptors [5,11,17].